Photo by Toa Heftiba on Unsplash

RSV programmes

Apr 27, 2020

I have done lots of work on cost-effectiveness of RSV for the UK and Europe.

This work help informed vaccination policy agaisnt RSV, leading to recommendations from the JCVI here and here.

Publications

Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination

David Hodgson, Neil Wilkins, Edwin van Leeuwen, Conall H. Watson, Jonathan Crofts, Stefan Flasche, Mark Jit, Katherine E. Atkins

January 2024 In Lancet Europe

This study compares the cost-effectiveness of long-acting monoclonal antibodies and maternal vaccines for RSV prevention in young children.

Code Project DOI Full Text

Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis

David Hodgson, Richard Pebody, Jasmina Panovska-Griffiths, Marc Baguelin, Katherine E. Atkins

January 2023 In JIDM

This study evaluates new RSV intervention strategies using mathematical modelling and economic analysis, highlighting the cost-effectiveness of seasonal programmes.

PDF Code Project DOI Full Text

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales

David Hodgson, Mihaly Koltai, Fabienne Krauer, Stefan Flasche, Mark Jit, Katherine E. Atkins

October 2022 In Vaccine

This study evaluates the cost-effectiveness of Nirsevimab intervention programmes for RSV prevention in England and Wales.

Code Project DOI Full Text